PanTher Therapeutics is a clinical-stage oncology company based in Watertown, MA, that is revolutionizing cancer care by developing sustained treatments engineered for localized applications. Their proprietary treatment platform, Sagittari, allows for targeted therapy that enhances therapeutic response while minimizing side effects.
At the core of PanTher's approach is the ability to provide targeted, sustained, and localized treatment, enabling more of the drug to reach and be retained at the tumor site. Their lead candidate, PTM-101, is a minimally invasive, implantable treatment for pancreatic cancer that provides direct, sustained release of the therapeutic agent at the tumor site. PanTher Therapeutics is actively building a pipeline of Sagittari platform product candidates and exploring co-development opportunities to address the highest unmet medical needs in oncology.
Generated from the website